Amgen Inc. SEC filings document the regulatory record for a Nasdaq-listed biotechnology company with common stock and registered debt securities. Its 8-K reports cover quarterly and annual earnings releases, Regulation G reconciliations for non-GAAP measures, free cash flow disclosures, material definitive agreements, executive leadership changes and capital markets transactions.
The company's proxy materials describe annual meeting matters, board governance, executive compensation and stockholder voting procedures. Other filings address senior note offerings under registration statements and indentures, Nasdaq listing and registration matters for debt securities, and formal exhibits that define the terms of financing, governance and corporate disclosure events.
Amgen Inc. executive David M. Reese reported routine equity compensation awards and a small tax-related share disposition. He received 2,912 shares of Common Stock as a grant on May 5, 2026, including 415 Dividend Equivalents, under Amgen’s Equity Incentive Plan. These Restricted Stock Units vest in four equal annual installments of 25% starting on May 5, 2027, with proration based on completed months of active employment in 2026, and will be settled in common shares on a one-to-one basis. He was also granted 19,002 non-qualified stock options at an exercise price of $329.59 per share, vesting in four equal annual installments of 25% beginning on May 5, 2027 and expiring on May 5, 2036. On May 6, 2026, 454 shares of Common Stock were disposed of at $329.59 per share to cover tax obligations, leaving him with 42,812 Common shares held directly.
Amgen executive Esteban Santos reported routine equity compensation and a small tax-related share disposition. He received 2,730 shares of Amgen common stock on May 5, 2026 as a grant under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan. These Restricted Stock Units vest in four equal annual installments of 25% each, beginning on May 5, 2027, and will be settled one-for-one in common shares as they vest.
On the same date, he was granted non-qualified stock options covering 17,814 shares of common stock at $329.59 per share, also vesting in four annual 25% installments starting on May 5, 2027 and expiring on May 5, 2036. On May 6, 2026, 427 shares of common stock valued at $329.59 per share were withheld to cover tax obligations, leaving him with 83,369 directly held shares. He also has 909.9906 shares held indirectly through a 401K plan.
ISHRAK OMAR reported acquisition or exercise transactions in this Form 4 filing.
Amgen director Omar Ishrak reported an equity award of 106.1925 shares of Common Stock on a grant/award basis, not an open-market purchase. Following this award, his direct holdings total 6,693.7361 shares of Amgen common stock.
The total includes 418 Dividend Equivalents (DEs) credited under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan. These DEs are linked to unvested Restricted Stock Units and will be paid out in shares on a one-to-one basis as those units vest.
HOLLEY CHARLES M reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. director Charles M. Holley reported updated equity holdings. On May 5, 2026, he received a grant or award of 128.9481 shares of Amgen common stock at no cash cost, increasing his direct ownership to 12,134.0331 shares.
He also reports indirect ownership of 1,260 shares through the Holley Family Trust. The reported holdings include 1,564 Dividend Equivalents credited to his unvested Restricted Stock Units, which are payable in Amgen common stock on a one-for-one basis as those units vest.
Drake Michael V reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. director Michael V. Drake received a stock award of 79.6444 shares of common stock on May 5. The grant was recorded at no per-share price, indicating compensation rather than an open-market purchase. After this award, his direct holdings total 5109.2869 shares.
The holdings figure includes 339 Dividend Equivalents granted under Amgen’s Second Amended and Restated 2009 Equity Incentive Plan. These Dividend Equivalents are tied to unvested Restricted Stock Units and will be paid out in common shares on a one-to-one basis as the units vest.
Amgen Inc. executive Esteban Santos, EVP of Operations, reported compensation-related share activity in Common Stock. On May 2, 2026, he had 1,338 shares withheld as a tax-withholding disposition in two F-code transactions at $329.82 per share, a non‑market mechanism used to satisfy tax obligations on equity awards rather than an open-market sale. He also reported 909.9906 shares held indirectly through the Company’s 401(k) Plan, representing interests in Amgen’s stock fund.
Amgen Inc. executive David M. Reese reported routine tax-related share dispositions. On May 2, 2026, a total of 1,433 shares of Amgen common stock were withheld at $329.82 per share to cover tax obligations, classified as tax-withholding dispositions rather than open-market sales.
A footnote notes that the reported holdings include 442 Dividend Equivalents tied to unvested Restricted Stock Units, which will be paid in common shares on a one-to-one basis as those units vest.
Amgen Inc. senior vice president of human resources Derek Miller reported routine share dispositions tied to tax withholding, not open-market sales. On May 2, 2026, a total of 365 shares of Amgen common stock were withheld at $329.82 per share to cover tax liabilities on equity awards.
A footnote explains that his holdings include 123 Dividend Equivalents credited under Amgen’s equity incentive plan, which will be paid out as common shares on a one-for-one basis as related restricted stock units vest.
Amgen Inc. SVP Rachna Khosla reported routine tax-withholding share dispositions. On May 2, 2026, a total of 225 shares of Amgen common stock were withheld at $329.82 per share to cover tax liabilities tied to equity awards, not as open-market sales. She continues to hold a direct stake in Amgen stock, and her holdings also reflect 73 dividend equivalents linked to unvested restricted stock units that will settle in shares as they vest.
Amgen Inc. senior vice president and chief compliance officer Nancy A. Grygiel reported multiple transactions in the company’s common stock. On May 4, 2026, she completed an open-market sale of 1,237 shares at an average price of $323.7272 per share. On May 2, 2026, two F-code tax-withholding dispositions of 116 and 126 shares at $329.82 per share were recorded to cover tax obligations. After these transactions, she directly holds 7,009 shares of Amgen common stock and has an additional 106.1864 shares indirectly through the company’s 401(k) Plan. Her holdings also reflect 72 Dividend Equivalents tied to unvested restricted stock units that pay out in shares as they vest.